Double vaccine attack: new hope for HPV-Positive throat cancer?
NCT ID NCT05799144
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 18 times
Summary
This study tests whether giving two different HPV vaccines along with the immunotherapy drug pembrolizumab can help shrink or control advanced throat cancer that has spread or come back. The trial enrolls 54 adults with HPV-positive oropharyngeal cancer whose tumors have a specific protein (PD-L1). The goal is to see if the combination boosts the immune system to fight the cancer better than pembrolizumab alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OROPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama Birmingham
RECRUITINGBirmingham, Alabama, 35249, United States
Contact
Contact
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.